drugset / Trial / NCT01536366

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

NCT01536366

Phase 1 Completed 27 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.

Timeline

Start
2009-06
Primary completion
2009-07
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 25 mg
Subject Repaglinide Small molecule 0.5 mg

Indications